Transforming Neurology Prior Authorization Automation

Klivira delivers comprehensive neurology prior authorization automation, transforming complex workflows for high-cost therapies and advanced diagnostics.

Revenue cycle leaders and prior authorization coordinators in neurology face unique challenges, from managing high-volume specialty drug PAs to navigating intricate payer policies for advanced imaging and procedures. Manual processes lead to significant administrative burden, delayed patient care, and increased denial rates. Klivira's platform is designed to address these specific pain points, integrating seamlessly with your EMR to automate the entire PA lifecycle.

The Unique Prior Authorization Landscape in Neurology

Neurology prior authorization is characterized by a high volume of complex requests for specialty drugs and advanced diagnostics. Therapies for conditions such as Multiple Sclerosis (MS), chronic migraine, Alzheimer's disease, and spinal muscular atrophy often require extensive documentation and adherence to stringent step therapy protocols. This complexity, coupled with ongoing re-authorization requirements, places a substantial burden on administrative staff.

Key PA Triggers in Neurology

MS disease-modifying therapies (DMTs) like ocrelizumab, ofatumumab, natalizumab, and oral agents.
Alzheimer's disease therapeutics such as lecanemab and donanemab, often requiring amyloid imaging or CSF biomarker confirmation.
Migraine prevention biologics including CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and oral gepants.
Spinal muscular atrophy and ALS treatments like nusinersen, onasemnogene abeparvovec, and risdiplam.
Botox for chronic migraine, spasticity, dystonia, and blepharospasm.
Advanced imaging, including brain MRI, MR angiography, advanced spectroscopy, and amyloid PET scans.
Neuromodulation procedures such as Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), and Responsive Neurostimulation (RNS).

Navigating Complex Documentation and Payer Policies

Payer policies for neurology services frequently align with AAN Practice Guidelines, demanding precise documentation. For MS DMTs, this includes McDonald criteria, EDSS scores, and prior therapy trials. Alzheimer's anti-amyloid antibodies require clinical AD diagnosis, amyloid confirmation, and MRI for ARIA screening. CGRP migraine prevention often necessitates headache diaries and documentation of prior preventive trial failures. Common denial reasons stem from unmet step therapy requirements or gaps in biomarker confirmation.

Klivira's Automated Workflow for Neurology Prior Authorization

Klivira's platform integrates directly with your EMR to automate prior authorization from order entry through approval. Utilizing SMART on FHIR and CDS Hooks, our system detects PA requirements at the point of care, preventing missed authorizations. It then automatically assembles required documentation, drawing from FHIR resources like DocumentReference, Condition, and Observation, tailored to payer-specific criteria and AAN guidelines.

Klivira's Impact on Neurology PA Workflows

Automated detection of PA requirements for high-cost neurology drugs and procedures at order entry.
Streamlined documentation assembly, reducing manual chart review and clinician callbacks.
Payer-specific submission routing via Da Vinci PAS, X12 278, or portal automation, ensuring optimal channel use.
Real-time status tracking and EMR write-back of authorization numbers, eliminating manual updates.
Automated denial reason parsing and intelligent routing for appeals or peer-to-peer reviews.
Management of periodic re-authorization for chronic neurology treatments like MS DMTs and Botox.

Seamless EMR and Payer Integration for Neurology

Our platform offers robust EMR integration, supporting SMART App Launch on FHIR for systems like Epic, Cerner / Oracle Health, athenahealth, MEDITECH Expanse, and eClinicalWorks. This enables seamless data exchange for documentation and real-time status updates. For payer connectivity, Klivira leverages Da Vinci PAS APIs, X12 278, and provider portal automation, ensuring that neurology prior authorization requests are submitted through the most efficient electronic channels available, compliant with standards like CMS-0057-F.

Addressing Specialty-Specific Workflow Constraints

Neurology PA workflows are often burdened by the need for periodic re-authorization for chronic treatments and the management of ongoing MRI monitoring requirements for many drugs. Klivira's system tracks these cycles, proactively initiating re-authorization requests and ensuring all necessary documentation, including updated MRI findings, is included. This proactive approach minimizes treatment delays and administrative overhead for both routine and time-sensitive neurology cases.

Frequently asked questions

How does Klivira handle re-authorization for chronic neurology therapies?

Klivira's platform tracks the re-authorization schedules for chronic neurology treatments, such as MS DMTs and Botox for chronic migraine. Our system proactively identifies upcoming re-authorization needs, automatically assembling updated clinical documentation from the EMR and submitting the request to the payer, ensuring continuous patient access to therapy.

What specific neurology drugs does Klivira's platform support for PA automation?

Klivira supports PA automation for a broad range of neurology drugs, including MS disease-modifying therapies (e.g., ocrelizumab, natalizumab), CGRP migraine biologics (e.g., erenumab, fremanezumab), Alzheimer's anti-amyloid antibodies (e.g., lecanemab), and Botox for various neurological indications. Our payer policy engine is continuously updated to cover the latest specialty pharmaceuticals.

How does Klivira integrate with our EMR for neurology orders?

Klivira integrates with leading EMRs like Epic, Cerner, and athenahealth using SMART App Launch on FHIR and CDS Hooks. This allows for real-time PA requirement detection at the point of order entry for neurology procedures or medications. Our system then pulls relevant clinical data directly from the EMR to populate PA requests and writes authorization numbers back to the patient chart upon approval.

Can Klivira help with denials for MS DMTs or CGRP biologics?

Yes, Klivira automates denial management for neurology-specific denials. Our system parses denial reasons (e.g., X12 CARC/RARC codes), identifies common issues like step therapy non-compliance for MS DMTs or CGRP biologics, and can auto-assemble appeal packets. For complex clinical necessity denials, it routes the case to a human for review or facilitates peer-to-peer scheduling.

Does Klivira account for AAN guidelines in its PA logic?

Klivira's payer policy engine incorporates clinical criteria often aligned with AAN Practice Guidelines. For example, our logic for MS DMTs considers McDonald criteria, EDSS scores, and prior treatment history. For Alzheimer's anti-amyloid antibodies, it accounts for amyloid confirmation and MRI screening protocols, ensuring documentation aligns with payer requirements derived from such guidelines.